Experts Discuss Potential Benefits, Harms, Safeguards of Using AI Chatbots for Mental Health — American Academy of Pediatrics

Read Article — Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, is quoted in an article about the Nov. 6 FDA advisory committee meeting on regulating AI chatbots for psychotherapy. "A product-centric approval process that could be too slow and can be rigid for the field could guarantee that a product that is approved would be obsolete by the time it's really deployed," said Jacobson, who told the committee about his work on Therabot, the first generative AI chatbot to undergo a clinical trial.